← Leaderboards
Gordon B. Mills
University Of California San Francisco
$27,749,983
Attributed
$49,177,526
Total exposure
24
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.5M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$64,178,779 · 27
By mechanism
U24$21,403,545 · 5
U01$13,432,028 · 4
U2C$9,720,788 · 1
U54$7,891,609 · 4
P50$6,524,199 · 6
R01$3,672,721 · 3
Top collaborators
- Han Liang19 shared
- John N Weinstein19 shared
- Rehan Akbani17 shared
- Benjamin Deneen7 shared
- Meera Nanjundan6 shared
- W K Alfred Yung6 shared
- Joe W. Gray5 shared
- Anil Korkut5 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Frederic M. Waldman$7,639,095
- Louis French Reichardt$12,483,705
- Colin C Collins$2,944,307
- Zena Werb$33,582,689
- Michael Fried$4,365,179
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorPathway InteractionsBaseResponseProteinsCell LineMolecularProteomicsSamplingProgramsResistanceSignal TransductionCellsMutationAlgorithmsCancer PatientFundingDesignClinical TrialsPharmaceutical PreparationsBiologicalSignal PathwayFuture
Grant awards (116)
Systematic Characterization and Targeting of Neomorphic Drivers in Cancer$856,656
U01 · FY2025 · CA · contact PI
The Cancer Proteome Atlas: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$802,657
U24 · FY2025 · CA
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.$527,746
U01 · FY2025 · CA · contact PI
Systematic Characterization and Targeting of Neomorphic Drivers in Cancer$813,823
U01 · FY2024 · CA · contact PI
The Cancer Proteome Atlas: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$712,495
U24 · FY2024 · CA
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.$501,790
U01 · FY2024 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast Cancer$923,254
U2C · FY2023 · CA
Systematic Characterization and Targeting of Neomorphic Drivers in Cancer$883,656
U01 · FY2023 · CA · contact PI
The Cancer Proteome Atlas: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$786,719
U24 · FY2023 · CA
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.$516,726
U01 · FY2023 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,747,063
U2C · FY2022 · CA
The Cancer Proteome Atlas: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$818,276
U24 · FY2022 · CA
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.$516,407
U01 · FY2022 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$1,851,265
U54 · FY2021 · CA
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,723,236
U2C · FY2021 · CA
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer$721,618
U01 · FY2021 · CA · contact PI
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.$540,450
U01 · FY2021 · CA · contact PI
Project 1: High Grade Cancers: Capitalizing on PARPness in Ovarian Carcinoma$344,121
P50 · FY2021 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,757,743
U2C · FY2020 · CA
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer$721,618
U01 · FY2020 · CA · contact PI
TCPA: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$689,191
U24 · FY2020 · CA
Project 1: High Grade Cancers: Capitalizing on PARPness in Ovarian Carcinoma$358,686
P50 · FY2020 · CA · contact PI
P4: A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer$302,813
P50 · FY2020 · CA · contact PI
Batch effects in molecular profiling data on cancers: detection, quantitation, interpretation, and correction$262,991
U24 · FY2020 · CA
Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform$255,498
U24 · FY2020 · CA
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,757,745
U2C · FY2019 · CA
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks$1,714,600
U54 · FY2019 · HG
TCPA: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$747,759
U24 · FY2019 · CA
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer$699,970
U01 · FY2019 · CA · contact PI
Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform$400,901
U24 · FY2019 · CA
Batch effects in molecular profiling data on cancers: detection, quantitation, interpretation, and correction$378,391
U24 · FY2019 · CA
P4: A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer$290,152
P50 · FY2019 · CA · contact PI
Project 1: High Grade Cancers: Capitalizing on PARPness in Ovarian Carcinoma$258,050
P50 · FY2019 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,811,747
U2C · FY2018 · CA
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks$1,714,600
U54 · FY2018 · HG
TCPA: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$796,328
U24 · FY2018 · CA
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer$739,554
U01 · FY2018 · CA · contact PI
Batch effects in molecular profiling data on cancers: detection, quantitation, interpretation, and correction$415,564
U24 · FY2018 · CA
Project 1: High Grade Cancers: Capitalizing on PARPness in Ovarian Carcinoma$370,022
P50 · FY2018 · CA · contact PI
P4: A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer$291,693
P50 · FY2018 · CA · contact PI
Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform$279,908
U24 · FY2018 · CA
TCPA: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$80,000
U24 · FY2018 · CA
P4: A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer$17,454
P50 · FY2018 · CA · contact PI
TCPA: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$796,328
U24 · FY2017 · CA
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer$739,551
U01 · FY2017 · CA · contact PI
Batch effects in molecular profiling data on cancers: detection, quantitation, interpretation, and correction$416,321
U24 · FY2017 · CA
Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform$413,299
U24 · FY2017 · CA
Project 1: High Grade Cancers: Capitalizing on PARPness in Ovarian Carcinoma$351,522
P50 · FY2017 · CA · contact PI
P4: A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer$311,990
P50 · FY2017 · CA · contact PI
TCPA: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$80,000
U24 · FY2017 · CA
Biological annotation of TCGA data$841,452
U01 · FY2016 · CA · contact PI
TCPA: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data$796,328
U24 · FY2016 · CA
Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform$420,664
U24 · FY2016 · CA
Batch effects in molecular profiling data on cancers: detection, quantitation, interpretation, and correction$418,519
U24 · FY2016 · CA
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)$312,500
U24 · FY2016 · CA
P4: A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer$295,325
P50 · FY2016 · CA · contact PI
Biological annotation of TCGA data$910,976
U01 · FY2015 · CA · contact PI
Biological annotation of TCGA data$1,097,803
U01 · FY2014 · CA · contact PI
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)$700,000
U24 · FY2014 · CA
Modeling response to P13K Target Therapies$488,526
U54 · FY2014 · CA · contact PI
Role of Rab25 and its Effectors in Breast Cancer Bioengenerics$165,318
P01 · FY2014 · CA · contact PI
P4 - Pers. Therapy for High-Grade Ovarian Cancer: Targeting PI3Kness & BRCAne$160,477
P50 · FY2014 · CA · contact PI
Modeling response to P13K Targeted Therapies$36,423
U54 · FY2014 · CA · contact PI
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)$1,880,091
U24 · FY2013 · CA
Biological annotation of TCGA data$853,708
U01 · FY2013 · CA · contact PI
Modeling response to P13K Target Therapies$430,118
U54 · FY2013 · CA · contact PI
P4 - Pers. Therapy for High-Grade Ovarian Cancer: Targeting PI3Kness & BRCAne$230,529
P50 · FY2013 · CA · contact PI
Role of Rab25 and its Effectors in Breast Cancer Bioengenerics$160,210
P01 · FY2013 · CA · contact PI
Modeling response to P13K Targeted Therapies$33,477
U54 · FY2013 · CA · contact PI
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)$1,587,106
U24 · FY2012 · CA
Biological annotation of TCGA data$948,524
U01 · FY2012 · CA · contact PI
Modeling response to P13K Target Therapies$452,883
U54 · FY2012 · CA · contact PI
Predictors of Resistance Dual VEGFR/EGFR Targeted Therapy of Head and Neck Cancer$387,152
P50 · FY2012 · CA · contact PI
The Role of Aberrant Splicing of EVl1 in Ovarian Cancer Pathophysiology$307,535
R01 · FY2012 · CA · contact PI
P4 - Pers. Therapy for High-Grade Ovarian Cancer: Targeting PI3Kness & BRCAne$184,534
P50 · FY2012 · CA · contact PI
Role of Rab25 and its Effectors in Breast Cancer Bioengenerics$170,431
P01 · FY2012 · CA · contact PI
Modeling response to P13K Targeted Therapies$36,491
U54 · FY2012 · CA · contact PI
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)$1,438,358
U24 · FY2011 · CA
Modeling response to P13K Target Therapies$490,403
U54 · FY2011 · CA · contact PI
Predictors of Resistance Dual VEGFR/EGFR Targeted Therapy of Head and Neck Cancer$363,040
P50 · FY2011 · CA · contact PI
The Role of Aberrant Splicing of EVl1 in Ovarian Cancer Pathophysiology$305,140
R01 · FY2011 · CA · contact PI
P4 - Pers. Therapy for High-Grade Ovarian Cancer: Targeting PI3Kness & BRCAne$175,173
P50 · FY2011 · CA · contact PI
Role of Rab25 and its Effectors in Breast Cancer Bioengenerics$170,430
P01 · FY2011 · CA · contact PI
Modeling response to P13K Targeted Therapies$38,624
U54 · FY2011 · CA · contact PI
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)$1,491,837
U24 · FY2010 · CA
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)$900,000
U24 · FY2010 · CA
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)$841,344
U24 · FY2010 · CA
Modeling response to P13K Target Therapies$562,459
U54 · FY2010 · CA · contact PI
Predictors of Resistance Dual VEGFR/EGFR Targeted Therapy of Head and Neck Cancer$399,737
P50 · FY2010 · CA · contact PI
The Role of Aberrant Splicing of EVl1 in Ovarian Cancer Pathophysiology$314,578
R01 · FY2010 · CA · contact PI
P4 - Pers. Therapy for High-Grade Ovarian Cancer: Targeting PI3Kness & BRCAne$180,145
P50 · FY2010 · CA · contact PI
Role of Rab25 and its Effectors in Breast Cancer Bioengenerics$175,700
P01 · FY2010 · CA · contact PI
Modeling response to P13K Targeted Therapies$41,740
U54 · FY2010 · CA · contact PI
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)$1,484,172
U24 · FY2009 · CA
The Role of Aberrant Splicing of EVl1 in Ovarian Cancer Pathophysiology$677,167
R01 · FY2009 · CA · contact PI
Predictors of Resistance Dual VEGFR/EGFR Targeted Therapy of Head and Neck Cancer$361,121
P50 · FY2009 · CA · contact PI
The Role of Aberrant Splicing of EVl1 in Ovarian Cancer Pathophysiology$314,578
R01 · FY2009 · CA · contact PI
Targeting the PI3K Pathway in Ovarian Cancer$211,121
P50 · FY2009 · CA · contact PI
The Role of Aberrant Splicing of EVl1 in Ovarian Cancer Pathophysiology$327,989
R01 · FY2008 · CA · contact PI
P-3: Predictors of Resistnace toDual VEGFR/EGFR Targeted Therapy of H&N Cancer$224,378
P50 · FY2008 · CA · contact PI
Targeting the PI3K Pathway in Ovarian Cancer$147,397
P50 · FY2008 · CA · contact PI
MMAC1/PTEN TUMOR SUPPRESSOR AND BREAST CANCER$269,658
R01 · FY2003 · CA
MMAC1/PTEN TUMOR SUPPRESSOR AND BREAST CANCER$262,425
R01 · FY2002 · CA
LPA IN INITIATION AND PROGRESSION IN OVARIAN CANCER$230,600
P01 · FY2002 · CA
PI-3 KINASE PATHWAY IN OVARIAN CANCER$230,600
P01 · FY2002 · CA
Phosphatidylinositol signaling in ovarian tumorigenesis, prognosis &therapy$0
P50 · FY2002 · CA
Phosphatidylinositol signaling in ovarian tumorigenesis, prognosis &therapy$0
P50 · FY2002 · CA
MMAC1/PTEN TUMOR SUPPRESSOR AND BREAST CANCER$255,405
R01 · FY2001 · CA
CD SIGNALING THROUGH EMT/ITK TYROSINE KINASE$197,707
R01 · FY2001 · CA
LPA IN INITIATION AND PROGRESSION IN OVARIAN CANCER$0
P01 · FY2001 · CA
Phosphatidylinositol signaling in ovarian tumorigenesis, prognosis &therapy$0
P50 · FY2001 · CA
PI-3 KINASE PATHWAY IN OVARIAN CANCER$0
P01 · FY2001 · CA
Phosphatidylinositol signaling in ovarian tumorigenesis, prognosis &therapy$307,567
P50 · FY2000 · CA
MMAC1/PTEN TUMOR SUPPRESSOR AND BREAST CANCER$248,590
R01 · FY2000 · CA
OVARIAN CANCER ACTIVATING FACTOR IN OVARIAN CANCER INITIATION AND PROGRESSION$230,600
P01 · FY2000 · CA
CD SIGNALING THROUGH EMT/ITK TYROSINE KINASE$191,949
R01 · FY2000 · CA